NCT01998035 2024-08-22Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid MalignanciesColumbia UniversityPhase 1/2 Terminated58 enrolled 11 charts
NCT01897012 2019-01-28Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasNational Cancer Institute (NCI)Phase 1 Completed26 enrolled
NCT02281279 2016-08-11Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaMayo ClinicPhase 1/2 Withdrawn
NCT00079443 2013-07-01FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaNational Cancer Institute (NCI)Phase 2 Terminated60 enrolled
NCT00042822 2011-05-17FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's LymphomaNational Cancer Institute (NCI)Phase 2 Completed